Last reviewed · How we verify
Centella Complex
Centella Complex, developed by the University of Roma La Sapienza, is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its unique mechanism of action, which differentiates it from existing treatments. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Centella Complex |
|---|---|
| Sponsor | University of Roma La Sapienza |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Topical and Oral Regimen for Skin Health (NA)
- Pain and Bleeding in Subjects With Acute Anal Fissure: Comparative Evaluation of Three Treatments (PHASE4)
- Irritation and Anal Bleeding in Patients Affected by Hemorrhoids. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Centella Complex CI brief — competitive landscape report
- Centella Complex updates RSS · CI watch RSS
- University of Roma La Sapienza portfolio CI